Print |
  • Text A A
  • PDxProstateSubPageGraphic_V2.jpg

    ERG_logo.png by fish

    ERG analysis by FISH identifies genomic changes in prostate cancer patients  which may be indicative of disease progression and poor overall and disease-specific survival.

    Researchers have identified two ERG alterations that are specifically related to poor prognosis:

    ERG gene deletions

    • In one study, deletion of ERG (5’), and extra copies of (3’) exhibited extremely poor prostate cancer-specific survival (25% survival at 8 years).1
    • Patients that had a normal ERG profile exhibited favorable prostate cancer-specific survival (90% survival at 8 years).1

    ERG deletion (EDel) + copy increase is associated with poor prognosis and prostate-cancer specific survival in conservatively managed patients.1

    ERG_deletion_graph.png

    ERG_EDel.png

     

    ERG_logo.png copy number increase

    Studies from Top NCCN Cancer Centers Have Shown that ERG Copy Number Increase Predicts Aggressive Disease and Outcome.

    ERG Copy Number Increase with 2+ EDel (CNID) event is most aggressive.2

    ERG gene polysomy (copy number increase) without fusion was significantly associated with recurrence (P-value = 0.01).3

    Men with ERG gene copy number increase without fusion were twice more likely to recur.3


    References

    1. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253–263.

    2. Gopalan A, Leversha MA, Satagopan JM, et al.  TMPRSS-ERG Gene Fusion is Not Associated with Outcome in Patients Treated by Prostatectomy.  Cancer Research. 2009;69(4):1400-1406.

    3. Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology. 2011;24:1511-1520.

    This test was developed by and its performance characteristics determined by PersonalizeDx. It has not been cleared or approved by the U.S. Food and Drug Administration. PersonalizeDx is a CLIA-accredited laboratory CLIA ID #05D2001811. This test is used for clinical purposes. The clinical validity of the test has been established based upon review of relevant literature. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity testing.